Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Worldwide Pain Management Drugs Industry to 2030 - Rise in Number of Cases of Chronic Disorders is Driving Growth

Research and Markets Logo

News provided by

Research and Markets

Mar 04, 2022, 06:45 ET

Share this article

Share toX

Share this article

Share toX

DUBLIN, March 4, 2022 /PRNewswire/ -- The "Global Pain Management Drugs Market, By Drug Class, By Indication, By Pain Type, By Drug Type, By Distribution Channel, Estimation & Forecast, 2017 - 2030" report has been added to ResearchAndMarkets.com's offering.

The global Pain Management Drugs market was valued at USD 71,238.7 Million in 2021 and is forecasted to reach USD 99,943.3 Million by the year 2030. The market is anticipated to register a CAGR of 3.92% over the projected period.

The pain management drugs market is anticipated to grow owing to the rise in number of cases of chronic disorders coupled with the rising healthcare expenditure and government support worldwide. Furthermore, growing number of surgical procedures and the increasing geriatric population are also estimated to fuel the market growth. However, the availability of alternatives such as pain reliever devices are expected to negatively impact the market growth.

Increasing incidence rate of chronic disorders is expected to boost the demand for pain management drugs for the treatment of pain associated with these disorders. According to the Centers for Disease Control and Prevention, as of December 2021, in the United States, 6 out of 10 adults suffer from a chronic disease and 4 out of 10 adults suffer from 2 diseases or more. These diseases include cancer, heart diseases, stroke, chronic lung disease, diabetes, Alzheimer's disease, and chronic kidney disease. Most or all of these diseases are associated with pain. Hence the rise in the number of cases of chronic disorders are expected to fuel the market growth.

Segments Overview:

The global Pain Management Drugs market is segmented the drug class, indication, pain type, drug type, and distribution channel.

By Drug Class,

  • NSAIDS
  • Anesthetics
  • Anticonvulsants
  • Anti-Migraine Agents
  • Antidepressants
  • Opioids
  • Nonnarcotic Analgesics

The opioids segment is estimated to hold the largest market share of around 31.9% owing to their increasing demand for relieving pain associated with major chronic disorders. The anesthetics segments is expected to surpass a market value of USD 9,000 million by 2026 and USD 11,764 million by 2030, owing to its high usage in surgeries.

By Indication,

  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia
  • Bone fracture
  • Muscle sprain
  • Acute appendicitis
  • Others

The neuropathic pain segment is anticipated to account for the largest market share of more than 15% owing to rising cases of neuropathic pain. According to an article published by the National Center for Biotechnology Information in March 2019, the prevalence of neuropathic pain in general population ranges between 3% to 17%. Moreover, the market size for acute appendicitis segment is estimated to hot USD 3,598.0 million by 2030 owing to the increasing prevalence of acute appendicitis.

By Pain Type,

  • Chronic Pain
  • Acute Pain

The acute pain segment is expected to hold the largest market share owing to the high popularity of acute pain management drugs globally and easy availability of these drugs through OTC distribution channels.

By Drug Type,

  • Generics
  • Branded

The branded segment is anticipated to grow at the fastest rate of around 4.1% over the projected period owing to the increasing popularity of branded drugs in the developed as well as developing economics.

By Distribution Channel,

  • Hospitals
  • Pharmacy Retail Stores
  • Online

The online segment's market size is estimated to account for 34% of the hospital segment's market size in 2021 and this share is expected to reach 37% by 2030. This is owing to the increasing number of e-pharmacy websites.

Regional Overview

Based on region, the global Pain Management Drugs market is divided into Europe, North America, Asia Pacific, South America, and Middle East & Africa.

The North America region is expected to hold the largest market share of more than 50% owing to the growing patient pool, rising geriatric population, and favourable regulatory scenario. According to the U.S. Census Bureau, as of August 2021, around 15.2 million people in the U.S., i.e. 1 in 6 or 16.5% of the population are aged 55 years and above.

Asia Pacific region witnessed the fastest growth rate of 5.33% during the forecast period owing to the rising healthcare expenditure and growing R&D investments. Furthermore, the presence of various generic players of pain management drugs in the region is also likely to contribute to the market growth.

Competitive Landscape

Key players operating in the global Pain Management Drugs market include Abbott Laboratories, Allergen Inc., Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly & Company, Endo Health Solutions, Inc., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Ono pharmaceutical Co., Ltd., Pfizer, Inc., Purdue Pharma L.P., Sorrento Therapeutics, Valeant Pharmaceuticals International Inc., Viatris Inc., WEX Pharmaceuticals, Zynerba Pharmaceuticals, and Other Prominent Players.

Key Questions Answered:

  • What is the market size and forecast of the Global Pain Management Drugs Market?
  • What are the inhibiting factors and impact of COVID-19 on the Global Pain Management Drugs Market during the assessment period?
  • Which are the products/segments/applications/areas to invest in over the assessment period in the Global Pain Management Drugs Market?
  • What is the competitive strategic window for opportunities in the Global Pain Management Drugs Market?
  • What are the technology trends and regulatory frameworks in the Global Pain Management Drugs Market?
  • What is the market share of the leading players in the Global Pain Management Drugs Market?
  • What modes and strategic moves are considered favorable for entering the Global Pain Management Drugs Market?

Key Topics Covered:

Chapter 1. Research Framework

Chapter 2. Research Methodology

Chapter 3. Executive Summary: Global Pain Management Drugs Market

Chapter 4. Global Pain Management Drugs Market Overview
4.1. Industry Value Chain Analysis
4.1.1. Drugs Provider
4.1.2. Research and Development
4.1.3. Distributor
4.1.4. End Users
4.2. Industry Outlook
4.2.1. Pain relief techniques
4.3. PEST Analysis
4.4. Porter's Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of Substitutes
4.4.4. Threat of New Entrants
4.4.5. Degree of Competition
4.5. Market Dynamics and Trends
4.5.1. Growth Drivers
4.5.2. Restraints
4.5.3. Challenges
4.5.4. Key Trends
4.6. Covid-19 Impact Assessment on Market Growth Trend
4.7. Market Growth and Outlook
4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2017-2030
4.7.2. Pricing Analysis
4.8. Competition Dashboard
4.8.1. Market Concentration Rate
4.8.2. Company Market Share Analysis (Value %), 2020
4.8.3. Competitor Product Mapping

Chapter 5. Global Pain Management Drugs Market Analysis, By Drug Class
5.1. Key Insights
5.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
5.2.1. NSAIDs
5.2.2. Anesthetics
5.2.3. Anticonvulsants
5.2.4. Anti-migraine Agents
5.2.5. Antidepressants
5.2.6. Opioids
5.2.7. Nonnarcotic Analgesics

Chapter 6. Global Pain Management Drugs Market Analysis, By Indication
6.1. Key Insights
6.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
6.2.1. Arthritic Pain
6.2.2. Neuropathic Pain
6.2.3. Cancer Pain
6.2.4. Chronic Back Pain
6.2.5. Postoperative Pain
6.2.6. Migraine
6.2.7. Fibromyalgia
6.2.8. Bone fracture
6.2.9. Muscle sprain
6.2.10. Acute appendicitis
6.2.11. Others

Chapter 7. Global Pain Management Drugs Market Analysis, By Pain Type
7.1. Key Insights
7.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
7.2.1. Chronic pain
7.2.2. Acute pain

Chapter 8. Global Pain Management Drugs Market Analysis, By Drug Type
8.1. Key Insights
8.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
8.2.1. Generics
8.2.2. Branded

Chapter 9. Global Pain Management Drugs Market Analysis, By Distribution Channel
9.1. Key Insights
9.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
9.2.1. Hospitals
9.2.2. Pharmacy Retail Stores
9.2.3. Online

Chapter 10. Global Pain Management Drugs Market Analysis, By Region/ Country

Chapter 11. North America Pain Management Drugs Market Analysis

Chapter 12. Europe Pain Management Drugs Market Analysis

Chapter 13. Asia Pacific Pain Management Drugs Market Analysis

Chapter 14. Middle East & Africa Pain Management Drugs Market Analysis

Chapter 15. South America Pain Management Drugs Market Analysis

Chapter 16. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
16.1. Abbott Laboratories
16.2. Allergen Inc.
16.3. Bayer AG
16.4. Boehringer Ingelheim
16.5. Bristol-Myers Squibb
16.6. Eli Lilly & Company
16.7. Endo Health Solutions, Inc.,
16.8. GlaxoSmithKline Plc.
16.9. Johnson & Johnson
16.10. Merck & Co. Inc.
16.11. Novartis AG
16.12. Ono pharmaceutical Co., Ltd.
16.13. Pfizer, Inc.
16.14. Purdue Pharma L.P.
16.15. Sorrento Therapeutics
16.16. Valeant Pharmaceuticals International Inc.
16.17. Viatris Inc.
16.18. WEX Pharmaceuticals
16.19. Zynerba Pharmaceuticals.
16.20. Other Prominent Players

For more information about this report visit https://www.researchandmarkets.com/r/u2trrn

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.